These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33747201)

  • 1. Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
    Deng Y; Hong X; Yu C; Li H; Wang Q; Zhang Y; Wang T; Wang X
    Oncol Lett; 2021 May; 21(5):344. PubMed ID: 33747201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
    Qiu H; Hu X; He C; Yu B; Li Y; Li J
    Front Genet; 2020; 11():12. PubMed ID: 32117435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 7. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of an immune-related gene-based prognostic index for bladder cancer.
    Tian Z; Meng L; Long X; Diao T; Hu M; Wang M; Liu M; Wang J
    Am J Transl Res; 2020; 12(9):5188-5204. PubMed ID: 33042413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
    Chen L; Lin J; Wen Y; Chen Y; Chen CB
    Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic model of 10 immune-related genes and identification of small molecule drugs in bladder urothelial carcinoma (BLCA).
    Xing Q; Liu S; Jiang S; Li T; Wang Z; Wang Y
    Transl Androl Urol; 2020 Oct; 9(5):2054-2070. PubMed ID: 33209669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis.
    Kang Y; Zhu X; Wang X; Liao S; Jin M; Zhang L; Wu X; Zhao T; Zhang J; Lv J; Zhu D
    Front Oncol; 2021; 11():641184. PubMed ID: 33816287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Inflammatory Response-Related Gene Signature Predicts Immune Status and Prognosis of Breast Cancer.
    Zhao R; Xie C; Gong Y; Wei S; Yuan M; Gan J; Chen W
    J Oncol; 2022; 2022():5468858. PubMed ID: 36467500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.
    Zhu K; Deng W; Deng H; Liu X; Wang G; Fu B
    PPAR Res; 2021; 2021():7056506. PubMed ID: 35027921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Development of Inflammatory Response-Related Genes Signature Associated With Prognosis Evaluation and Immune Status of Bladder Cancer.
    Zheng H; Luo W; Li Y; Peng G; Zhou D; Tang D; Cheng J; Wu S
    Front Cell Dev Biol; 2022; 10():837849. PubMed ID: 35309900
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
    Qi X; Qi C; Qin B; Kang X; Hu Y; Han W
    Front Oncol; 2020; 10():541330. PubMed ID: 33072571
    [No Abstract]   [Full Text] [Related]  

  • 19. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma.
    Qin R; Li C; Wang X; Zhong Z; Sun C
    Cancer Cell Int; 2021 Jul; 21(1):378. PubMed ID: 34266418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.